Revive Therapeutics Advances Research Program of Cannabinoid-Based Therapies Targeting Liver Diseases

TORONTO, Jan. 30, 2018 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company“) (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel cannabinoid solutions, today announced the advancement of the research program to evaluate Cannabidiol (“CBD”) in the treatment of Autoimmune Hepatitis (“AIH”), a rare liver disease. The research will be overseen by Sanyal Biotechnology LLC (“SanyalBio”), the Company’s strategic research partner for liver diseases.

“We are very excited to advance the development of cannabidiol for the potential treatment of autoimmune hepatitis with Sanyal Biotechnology,” said Fabio Chianelli, President of Revive. “The research

...read more at https://globenewswire.com/news-release/2018/01/30/1314150/0/en/Revive-Therapeutics-Advances-Research-Program-of-Cannabinoid-Based-Therapies-Targeting-Liver-Diseases.html

by